Novel fusion protein derived from vasostatin 30 and vasoinhibin II-14.1 potently inhibits coronary endothelial cell proliferation

dc.contributorHumana Press Inc
dc.creatorVázquez Rodríguez, Gabriela
dc.creatorGonzález Castillo, Maria del Carmen
dc.creatorDe León Rodríguez, Antonio
dc.date2018-06-07T20:16:50Z
dc.date2018-06-07T20:16:50Z
dc.date2013-07
dc.date.accessioned2023-07-17T22:03:19Z
dc.date.available2023-07-17T22:03:19Z
dc.identifierVazquez Rodriguez, G., Gonzalez, C. & De Leon Rodriguez, A. Mol Biotechnol (2013) 54: 920. https://doi.org/10.1007/s12033-012-9642-4
dc.identifierhttp://hdl.handle.net/11627/3869
dc.identifierhttps://doi.org/10.1007/s12033-012-9642-4
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/7543443
dc.description"Angiogenesis has been considered an important target for cancer therapy. The inhibition of angiogenesis represents a promising strategy for anti-cancer treatment, tumor growth inhibition, and metastasis. Vasostatin 30 (Vs30), and the 14.1 kDa vasoinhibin (Vi-II-14.1) are two peptides with remarkable anti-tumor and anti-angiogenic effect. The aim of this study was to produce a novel fusion protein between Vs30 and Vi-II-14.1, denominated VS_VI, to obtain a new protein with higher biological activity. The protein fusion genes were cloned into a T7 promoter-based vector, expressed in Escherichia coli BL21-SI and purified by affinity column chromatography. In vitro assays showed that the recombinant fusion protein inhibited rat coronary endothelial cell proliferation at 65.5 % at 10 nM, whereas recombinant Vs30 and Vi-II-14.1 inhibited at 33 and 50.5 % respectively, at the same concentration. The results showed that VS_VI is significantly more active than the Vs30 and Vi-II-14.1 separately. In addition, a practical classification of the vasoinhibins based on the peptide origin and theoretical molecular weight is proposed. This is the first study to produce a new fusion protein derived from Vs30 and Vi-II-14.1, both of them proposed as promising therapeutic agents."
dc.formatapplication/pdf
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rightsAcceso Abierto
dc.subjectAngiogenesis
dc.subjectEndothelium
dc.subjectCell proliferation
dc.subjectFusion protein
dc.subjectRecombinant protein
dc.subjectBIOLOGÍA MOLECULAR
dc.titleNovel fusion protein derived from vasostatin 30 and vasoinhibin II-14.1 potently inhibits coronary endothelial cell proliferation
dc.typearticle


Este ítem pertenece a la siguiente institución